Biobanking has attractive prospects in Asia

Updated on 12 June 2012

Recently there is an upward trend for stem cell activity within Asia. This has resulted in the increased sales of high throughput screening devices. Consequently, the demand for storage of cord blood and stem cell in biobanks has increased. The private sector targets more on the cord and stem cell banking when compared to any other tumor or tissue repositories which are more public in nature.

Adoption of automation is slow but steady in Asia. This will also result in a slow down for the adoption of tools in other economies for example US, and Africa. The market has to develop in terms of operating private biobanks for profit. Additionally, legal and ethical issues need to be sorted out in order to enable the best use of biospecimens stored in public biobanks.

List of important biobanking projects/centers in Asia

Region  Biobanks 
Singapore  NUS-NUH Tissue Repository, SingHealth Tissue Repository
Malaysia UMCRI Tumour Tissue Bank, Cryocord Premiere stem cell bank
Japan  RIKSEN Bioresource center cell bank
China Institutional Tissue Bank Fudan university, China cord blood corporation
Korea National Biobank of Korea (NBK) 
India ICMR National Tumour Tissue Repository, TCS Life Sciences (The Chatterjee Group)


1 3 Next

1Comment

Comment 1 - 1 of 1

Samuel B 19 June 2012 at 05 PM

very nice article..good information

Reply

Leave a Reply

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X